Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Document › Details

Ablynx N.V.. (2/23/17). "Press Release: Ablynx Announces 2016 Rull Year Results. Significant Progress in Key Pre-clinical and Clinical Development Programmes". Ghent.

Organisation Organisation Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)
  Group Ablynx (Group)
Products Product caplacizumab (anti-vWF Nanobody)
  Product 2 vobarilizumab (ALX-0061, anti-IL-6R Nanobody)
Persons Person Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry)
  Person 2 Vermeersch, Marieke (Ablynx 201106 Investor Relations Manager)

Record changed: 2017-05-20


Picture [iito] – Putting Information into Context 600x102px

More documents for Ablynx (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 600x60px

» top